| Document |
Document Title |
|
WO/2020/239517A1 |
Mesoionic imidazolium compounds of formula (I) and their uses for combating animal pests. The present invention relates to compounds of formula (I), wherein A, W, Y, T and R1 are defined as in the description, and to the stereoisomers, s...
|
|
WO/2020/236940A1 |
The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and ar...
|
|
WO/2020/237025A1 |
The present disclosure relates generally to certain ene-oxindole compounds, pharmaceutical compositions comprising thereof. Also disclosed are methods of making and using said compounds and pharmaceutical compositions. The compounds and ...
|
|
WO/2020/234636A1 |
Present invention relates to the novel heterocyclic compounds of the general formula (I) their tautomeric forms, their stereoisomers and their pharmaceutically acceptable salts etc. The invention also relates to pharmaceutical compositio...
|
|
WO/2020/232655A1 |
Presented is an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound of the present disclosure, it is possible to provide an organic elect...
|
|
WO/2020/233645A1 |
Provided are macrolide derivatives represented by the formula (I), a preparation method thereof, and an application of the macrolide derivatives as one or more protein kinase inhibitors in TRK, ALK, and ROS1.
|
|
WO/2020/234333A1 |
The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositio...
|
|
WO/2020/234389A1 |
The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient...
|
|
WO/2020/236556A1 |
The present invention relates to methods of preparing substituted indole derivatives of general formula (I) : in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, and intermediate compounds useful for preparing said compounds....
|
|
WO/2020/228747A1 |
Provided are novel substituted macrocycles compounds, pharmaceutically acceptable salts, solvates and hydrates thereof. The compounds and compositions have protein kinases inhibitory activities and are expected to be useful for the treat...
|
|
WO/2020/228745A1 |
Disclosed is a new crystal form of a tetrahydroisoxazolo[4,3-c]pyridine compound against HBV, and in particular, disclosed are a crystal form of a compound of formula (I), a hydrate thereof, a crystal form of the hydrate thereof, and the...
|
|
WO/2020/198670A9 |
Methods for treating hedgehog pathway-dependent cancers are provided. Aspects of the methods include the inhibition of hedgehog pathway-dependent cancer growth, proliferation, or metastasis that is promoted by hedgehog pathway signaling....
|
|
WO/2020/226532A1 |
Influenza is an acute respiratory tract infection caused by the influenza virus. In light of the fact that influenza presents a serious threat to public health, the search for new anti-influenza drugs with improved characteristics is exp...
|
|
WO/2020/224208A1 |
Provided are crystals of (((R)-12'-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-
11-yl)-6',8'-dioxo-6',8',12',12a'tetrahydro-1'H-,4'H-spiro[c
yclopropane-1,3'-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]tria
zine]-7'-yl)oxy)methyl methyl...
|
|
WO/2020/221272A1 |
The present disclosure relates to an indole macrocyclic derivative, a preparation method therefor and use thereof in medicine. Specifically, the present disclosure relates to an indole macrocyclic derivative represented by general formul...
|
|
WO/2020/221824A1 |
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV rep...
|
|
WO/2020/221239A1 |
Disclosed are an oxazaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or form...
|
|
WO/2020/223558A1 |
The present application provides tricyclic amine compounds, which are inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.
|
|
WO/2020/221006A1 |
The present invention relates to the technical field of biomedicine, and specifically relates to a BET inhibitor, and a preparation method and use thereof. The present invention improves on the structure of prior art BET inhibitors to ob...
|
|
WO/2020/221826A1 |
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV rep...
|
|
WO/2020/221816A1 |
The present invention relates generally to novel antiviral agents. Specifically, the present invention relates to compounds which can inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV rep...
|
|
WO/2020/216350A1 |
Provided are quinoline derivative compounds of formulae (I), (II) and (III) with an inhibitory effect on mTOR and applications of their pharmaceutically acceptable salts, their stereoisomers, their hydrates or their solvates in preparati...
|
|
WO/2020/212256A1 |
The invention discloses a process for the preparation of maytansinoid esters of formula (I) comprising a thiol or disulphide group wherein R1, R4 and R5 and the asterisk are as defined in the description, by reacting maytansinol with an ...
|
|
WO/2020/212434A1 |
The present invention is directed to fused isoindolin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2.
|
|
WO/2020/207483A1 |
Disclosed are a crystal form of an EGFR inhibitor and a preparation method therefor. Further disclosed is an application of the crystal form in preparing a drug for treating non-small cell lung cancer, especially an application in prepar...
|
|
WO/2020/207941A1 |
The application relates to heterocyclic compounds of the general formula (I), compositions comprising such compounds, a process for preparing these compounds and their medical use. The compounds act as monoacylglycerol lipase (MAGL) inhi...
|
|
WO/2020/207279A1 |
The present invention relates to a method for modifying or marking an amino group in a molecule, wherein the amino group in the molecule is modified or marked with oxazoline quaternary ammonium salt shown in the following formula 1, wher...
|
|
WO/2020/203638A1 |
A hydride ion-containing composition which contains dissociative hydride ions and a solvent. It is preferable that the dissociative hydride ions are stabilized dissociative hydride ions. It is also preferable that the hydride ion-contain...
|
|
WO/2020/200945A1 |
A process for the preparation of midostaurin with high purity, particularly a process for the preparation of midostaurin with a content of oxidation impurities lower than 0.1% comprising the treatment of crude midostaurin or staurosporin...
|
|
WO/2020/200161A1 |
The present invention relates to a salt of an indazolyl-containing tricyclic derivative and a crystal form thereof. In particular, the present invention relates to a crystal form of a compound of general formula (I), a preparation method...
|
|
WO/2020/203610A1 |
Provided is a medicinal drug for treating or preventing rheumatoid arthritis. As a medicinal drug for treating or preventing rheumatoid arthritis, the present invention uses, as an active ingredient, a compound that has an effect of bloc...
|
|
WO/2020/204402A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic layer placed between the first electrode and the second electrode;...
|
|
WO/2020/205867A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2020/200209A1 |
Provided are an aromatic amine compound and a use thereof in the preparation of AR and BRD4 dual inhibitors and regulators. Specifically provided is the compound shown in formula I, said compound having dual inhibitory effects on AR and ...
|
|
WO/2020/202205A1 |
The invention provides a novel and practical route of synthesis the substituted diol intermediates, 1,1-dialkylethane-1,2-diols, useful for the preparation of various 6-nitro-2,3-dihydroimidazo[2,1-b]oxazole containing drugs. Specificall...
|
|
WO/2020/203609A1 |
Provided is a medicinal drug for treating or preventing pruritus. As a medicinal drug for treating or preventing pruritus, the present invention uses, as an active ingredient, a compound that has an effect of blocking the Cav3.2 T-type c...
|
|
WO/2020/194209A1 |
Described herein are compounds of Formula (I) that are inhibitors of mTORC1, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
|
|
WO/2020/198583A1 |
Provided herein are compounds of Formulas (I), (II), (III), and (IV) and subformulas thereof, wherein the variables are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I), (II), (III...
|
|
WO/2020/193511A1 |
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as HPK1 inhibitors, useful for treating diseases such as cancer.
|
|
WO/2020/194237A1 |
Methods of rapidly inhibiting efflux from a cell, sensitizing a drug-resistant cell to a drug and treating a subject with a drug-resistant pathology, by administering tetrahydrocannabinolic acid (THCa), cannabidiol (CBD) or a combination...
|
|
WO/2020/192750A1 |
Provided are a thienoheterocyclic derivative, a preparation method therefor and the medical use thereof. In particular, provided are a thienoheterocyclic derivative represented by general formula (I), a preparation method therefor, a pha...
|
|
WO/2020/194160A1 |
Disclosed are the macrocyclic compounds having the general Formula (I) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, and their combination with suitable medicament, corresponding processes for the synthesi...
|
|
WO/2020/188467A1 |
Disclosed are compounds containing tricyclic heteroaryl. Specifically, provided are a compound having a structure represented by the following formula (I), a pharmaceutical composition containing the compound of formula (I), as well as i...
|
|
WO/2020/180709A1 |
A scaled process of preparing maytansinol, FORMULA II, is provided by reacting a compound of Formula I, wherein R is selected from the group consisting essentially of alkyl, branched alkyl, aryl, alkenyl, alkynyl, as well as substituted ...
|
|
WO/2020/177653A1 |
The present invention relates to a pyrazine derivative, an application thereof in inhibiting SHP2, and a compound of formula (I) or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels thereof. The str...
|
|
WO/2020/181040A1 |
Cyclic amino-pyrazinecarboxamide compounds, salts, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in the treating of dise...
|
|
WO/2020/177715A1 |
The present invention belongs to the field of medicine, and relates to an influenza virus replication inhibitor and a use thereof, and provided thereby are a novel compound as an influenza virus replication inhibitor and a preparation me...
|
|
WO/2020/180127A1 |
The present invention relates to a novel compound having excellent electron transport ability and luminescence, and an organic electroluminescent device which comprises same in one or more organic layers and thus has improved characteris...
|
|
WO/2020/181025A1 |
The present disclosure relates to solid state forms of baloxavir marboxil, processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.
|
|
WO/2020/178282A1 |
The specification relates to compounds of Formula (A) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them an...
|
